AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02653547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-frequency multisite two weeks
Description: Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
Study NCT02834247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets.
Study NCT01759108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rebamipide
Description: Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
Study NCT01759108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
Study NCT02808130 — intervention group
Intervention type: OTHER
Intervention: hyperlipidemia, periodontitis, gingivitis
Description: GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva
Study NCT00470574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21
Study NCT00470574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine
Study NCT00470574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study NCT00470574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Study NCT00470574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01229423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Description: One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.
Study NCT00455507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Two 10 mg KW-6002 tablets orally once daily for 12 weeks
Study NCT00455507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Two 20 mg tablets orally once a day for 12 weeks
Study NCT01578304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imidafenacin
Description: Tablet, 12 weeks twice daily
Study NCT00455507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets orally once daily for 12 weeks
Study NCT02424929 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sedation
Description: Propofol anesthesia administered during entire surgery.
Study NCT02424929 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Original Surgery
Description: No intervention, surgery will be conducted as usual. With sedation only during the drilling of the burr holes.
Study NCT02834247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenous infusion.
Study NCT01307462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: Given inhaled PO
Study NCT00636909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: preparative cytoreduction
Study NCT00636909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: preparative cytoreduction
Study NCT00636909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: immunosuppressive therapy
Study NCT00636909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: immunosuppressive therapy
Study NCT00636909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: foster engraftment
Study NCT02563678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen therapy
Study NCT02563678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: Hyperbaric oxygen therapy
Study NCT01307462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Given PO
Study NCT02563678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Air/Oxygen
Description: Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber
Study NCT02563678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen
Description: Breathing 100% oxygen at normal, atmospheric pressure
Study NCT01091389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally Thoracoscopic PV isolation
Description: Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
Study NCT00988754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School children and adolescents as health experts
Description: Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
Study NCT00076687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18
Study NCT00076687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18
Study NCT00076687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline injection at Day 1, Week 12, Week 18
Study NCT04965545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: low copper diet
Description: All patients with wilson disease should receive low copper diet
Study NCT01132547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyproheptadine hydrochloride
Description: Given orally
Study NCT01578304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fesoterodine
Description: Tablet, 12 weeks once daily
Study NCT01643122 — intervention group
Intervention type: OTHER
Intervention: No drug
Description: Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).
Study NCT01643122 — intervention group
Intervention type: OTHER
Intervention: No drug
Description: Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
Study NCT00864188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: no bacterial strains
Description: Glucono-Delta-Lactone acidified milk containing no bacterial strains
Study NCT00864188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: One probiotic strain - Lactobacillus paracasei NCC2461
Description: Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.
Study NCT00864188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus
Description: Fermented milk containing two standard yogurt bacterial strains.
Study NCT00864188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus
Description: Fermented milk containing two standard yogurt bacterial strains.
Study NCT00864188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit B2, B3, C and E, Beta Carotene and Oil
Description: Fermented milk containing nutritional supplements
Study NCT05141968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplements (2000 IU/day)
Description: The interventional (experimental) group received vitamin D supplements (2000 IU/day). According to previous studies and after the direct supervision from the treating pediatrician and endocrinologist, the best preparation and dosage of vitamin D was used (According to FDA the recommended dose for children age 1 year and older is 2,000 IU/day).
Study NCT01970878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT 003)
Description: GFF MDI administered as two puffs BID
Study NCT01970878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI (PT001)
Description: GP MDI administered as two puffs BID
Study NCT01132547 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02225522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid whole genome sequencing (StatSeq)
Description: Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
Study NCT01970878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI (PT005)
Description: FF MDI administered as two puffs BID
Study NCT01970878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Description: Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
Study NCT04214093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0466
Description: In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort.
Study NCT04323800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti- SARS-CoV-2 Plasma
Description: SARS-CoV-2 convalescent plasma (1 unit; \~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320
Study NCT04323800 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 non-immune Plasma
Description: Normal human plasma collected prior to December 2019
Study NCT00489554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: Intramuscular injection, 3 doses.
Study NCT01307462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin
Description: Given PO
Study NCT04580095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI algorithm for apical foreshortening in echocardiography
Description: The algorithm is based on artificial intelligence, giving the sonographer performing the echocardiographic exam real-time feedback on left ventricular apical foreshortening.The algorithm is developed using deep learning techniques by technologists at the Department of Circulation and Medical Imaging, NTNU.
Study NCT03708666 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telemonitoring of blood pressure
Description: Blood pressure monitoring at least once a week.
Study NCT04280185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: HIPEC is a way of intraperitoneal chemotherapy
Study NCT00483600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux
Description: injections of 2.5mg every other day for 4 weeks
Study NCT03976882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: Hetrombopag
Study NCT03976882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03647267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Vitreolysis (C3F8 injection)
Description: Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.
Study NCT03647267 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation
Description: No intervention; sham injection only
Study NCT02454062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-114
Description: TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.
Study NCT02454062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)
Study NCT04792684 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Description: Evaluate the performance of a preliminary panel of biomarkers
Study NCT03874039 — intervention group
Intervention type: DEVICE
Intervention: Gas sensor
Description: The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.
Study NCT03874039 — intervention group
Intervention type: DEVICE
Intervention: Sweat Sensor
Description: The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.
Study NCT03794674 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: No intervention, since this is a validation study
Study NCT03954613 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ebicomb
Description: Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
Study NCT03954613 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ebicomb
Description: Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
Study NCT01882868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Pharmaceutical form: Concentrated solution (100 mg/4 mL \[25 mg/mL\], 200 mg/8 mL \[25 mg/mL\]) for infusion; Route of administration: Intravenous
Study NCT01882868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate
Description: Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
Study NCT01882868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
Study NCT01882868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
Study NCT04544683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cervical Transforaminal Epidural Injection with dexamethasone sodium phosphate
Description: Transforaminal epidural steroid injection: Injection of 1 to 2 mL of 1% lidocaine to the skin and subcutaneous tissues, a 25-gauge spinal needle will be placed at the level and side of radicular pathology, based on clinical correlation of symptoms/signs and magnetic resonance imaging findings. Advancement to the appropriate target position in the neuroforamen will be performed under fluoroscopic guidance. Satisfactory target position achieved and confirmed in both anterior-posterior and oblique views, 0.5 to 1 mL of contrast will be injected under live fluoroscopic observation with or without digital subtraction angiography depending on suggestion of vascular uptake. Upon confirmation of a satisfactory epidural contrast pattern without vascular uptake, the injectate will be delivered: dexamethasone sodium phosphate 1mL (10mg/mL) and 0.5 ml of 1% preservative-free lidocaine (total volume 1.5 mL).
Study NCT02593825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: START-Play intervention
Description: The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill.
Study NCT02593825 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Business as usual
Description: May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
Study NCT03618316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin
Description: 2 singles oral doses of imeglimin 1,500 mg (one at day 1 and one at day 8)
Study NCT03618316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine
Description: 400 mg of cimetidine bid from Day 5 to Day 10
Study NCT04119596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA gene sequencing
Description: Taking a stool sample for gut microbiome DNA sequencing
Study NCT03958409 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: measurements to evaluate metabolic bone disease
Description: The participants will be evaluated for a) Mineral metabolism: blood calcium, phosphorus, PTH, 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c) Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically. The bone mass at the lumbar spine, wrist, hip and total body bone mass at 3, and 18 months.
Study NCT03958409 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Blood tests (Ca, Phos, PTH- mineral lab, 25OHVitD);Pregnancy Test (if applicable); dual energy X-ray absorptiometry (DXA); Bone Biopsy only if clinically indicated; treatment as clinically indicated.
Study NCT04647929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Santen PRESERFLO MicroShunt
Description: the PRESERFLO MicroShunt will be implanted to increase aqueous humor outflow
Study NCT02143609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen
Description: Nocturnal nasal oxygen during stay at 2048 m
Study NCT02143609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Description: Nocturnal nasal oxygen during stay at 2048 m
Study NCT04119596 — intervention group
Intervention type: GENETIC
Intervention: DNA-microarray genotyping
Description: Taking a saliva sample for genotyping
Study NCT02364934 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
Study NCT02143609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sham oxygen (room air)
Description: Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m
Study NCT02143609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sham oxygen (room air)
Description: Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m
Study NCT02364934 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
Study NCT03102931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced ROS/RNS content products
Description: Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.